Glucagen Hypokit

Glucagen Hypokit is a prescription glucagon product marketed in the European Union. It contains the peptide hormone glucagon as the active ingredient, supplied in an injectable form for intramuscular or subcutaneous administration. The kit is used to rapidly raise blood glucose levels in patients experiencing severe hypoglycemia. The kit includes a ready‑to‑use syringe and detailed guidance, allowing rapid administration in urgent situations for patients with diabetes.

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia when rapid glucose elevation is required.

- Acute management of insulin‑induced hypoglycemia in adults and children. - Emergency treatment for hypoglycemic episodes unresponsive to oral glucose. - Use in situations where the patient is unconscious, unable to swallow, or has seizures. - Administration by trained caregivers or medical personnel in outpatient or hospital settings. - Adjunct therapy for patients with adrenal insufficiency experiencing hypoglycemic events.

The most frequently reported adverse events after glucagon injection are generally mild and transient. These effects typically resolve without intervention, but monitoring after administration is recommended.

Common: - Nausea or vomiting, usually occurring within minutes of injection. - Flushing, warmth, or mild pain at the injection site. - Transient headache lasting a few minutes. - Temporary increase in heart rate (tachycardia) that subsides quickly. - Dizziness or light‑headedness shortly after injection.

Serious: - Severe allergic reaction (anaphylaxis) presenting as rash, itching, swelling, or difficulty breathing. - Marked hypotension or cardiovascular collapse, which is rare but requires immediate care. - Persistent hyperglycemia (blood glucose > 250 mg/dL) that may need medical management.

Before using Glucagen Hypokit, certain safety considerations should be reviewed to minimize risk.

- Verify the diagnosis of severe hypoglycemia and confirm that oral glucose is ineffective or not feasible. - Ensure correct reconstitution and dosage according to the product instructions. - Assess for a history of hypersensitivity to glucagon or any component of the kit. - Use caution in patients with pheochromocytoma, adrenal insufficiency, or cardiovascular disease. - Avoid administration in patients with known insulinoma or uncontrolled diabetes without medical supervision. - Store the kit at controlled room temperature and protect from light; discard after the expiration date. - Train caregivers and patients on proper injection technique and emergency response.

Glucagon may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Avoid concurrent use with beta‑blockers that may blunt the expected rise in blood glucose. - Avoid administration immediately after high‑dose insulin therapy without monitoring glucose levels.

Use with caution: - Use with caution in patients receiving oral hypoglycemic agents, as rapid glucose changes can occur. - Use with caution when combined with catecholamines or vasopressors, which may alter cardiovascular response. - Use with caution in individuals on anticoagulants if intramuscular injection is performed, due to bleeding risk.